Innovative Bispecific Nanobody Targeting MS4A1 and TNFRSF17 for Autoimmune Disease Therapy
VHH-P289 is a bispecific, humanized nanobody developed to selectively target membrane spanning 4-domains A1 (MS4A1) and TNF receptor superfamily member 17 (TNFRSF17). Engineered for the treatment of autoimmune disease, this novel nanobody is currently at the Biological Testing stage. By precisely engaging both MS4A1 and TNFRSF17, VHH-P289 represents a promising approach to modulate key immune pathways implicated in autoimmunity. The molecular specificity and advanced engineering of VHH-P289 position it as a potential next-generation biologic for autoimmune disease management.
| Candidate | VHH-P289 |
| Target | membrane spanning 4-domains A1 (MS4A1) TNF receptor superfamily member 17 (TNFRSF17) |
| Modality | humanized bispecific VHH |
| Indication | Autoimmune Disease |
Licensing Opportunity
VHH-P289 is available for out-licensing opportunities. We invite partners interested in advancing this novel bispecific nanobody for autoimmune disease therapy to engage in collaboration discussions.
Contact UsDevelopment Phase
| Program | Research | Preclinical | Phase 1 |
|---|---|---|---|
| VHH-P289 |
Modality
VHH-P289 employs a bispecific nanobody modality, consisting of two distinct single-domain antibodies that recognize human B-cell maturation antigen and CD20, fused through a flexible a2 linker. As a nanobody, VHH-P289 offers superior properties such as a small molecular size, robust stability, and high solubility. These structural advantages enable enhanced tissue penetration and the possibility of alternative routes of administration, which are particularly beneficial in autoimmune disease therapy. The molecule is expressed efficiently in Escherichia coli BL21 cells, facilitating scalable and cost-effective biomanufacturing.
Target
MS4A1 and TNFRSF17 are central to B cell biology. MS4A1 is a transmembrane protein expressed primarily on the surface of B cells, involved in their activation and proliferation. TNFRSF17 is present on plasma cells and is crucial for B cell survival and differentiation. Both MS4A1 and TNFRSF17 play pivotal roles in the pathogenesis of autoimmune disease due to aberrant B cell responses. Targeting MS4A1 and TNFRSF17 allows for selective modulation of B cell subsets while sparing other immune components. The dual targeting by VHH-P289 of MS4A1 and TNFRSF17 embodies a strategic approach to simultaneously address multiple pathological mechanisms in autoimmune disease, offering broad therapeutic potential and meaningful clinical differentiation.
Mechanism of Action
VHH-P289 exerts its therapeutic effect through dual and simultaneous engagement of MS4A1 and TNFRSF17. By binding MS4A1 (CD20), VHH-P289 enables selective modulation or depletion of B cells implicated in autoimmunity. Targeting TNFRSF17 (associated with BCMA biology) further disrupts aberrant B cell survival signals, particularly affecting long-lived plasma cells. Through the unique format as a bispecific signal transduction modulator, VHH-P289 may induce synergistic inhibition of B cell pathogenicity and contribute to immune homeostasis. The flexible nanobody platform also provides scope for adaptation, such as payload conjugation or multi-specific architectures, to further optimize immunomodulatory therapies for autoimmune disease.
Autoimmune Disease
Autoimmune diseases encompass a heterogeneous group of conditions characterized by the immune system mounting an attack against host tissues, leading to chronic inflammation and tissue damage. Globally, these disorders affect millions of individuals and represent a substantial burden in terms of morbidity and healthcare costs. The prevalence includes well-known diseases such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis. Current standard-of-care involves immunosuppressants, corticosteroids, and biologic agents, many of which are associated with limited efficacy, side effects, and increased risk of infections. Unmet medical needs include the development of targeted therapies that can provide durable remission while minimizing systemic immune suppression. VHH-P289, with its bispecific mechanism targeting MS4A1 and TNFRSF17, holds the promise to selectively modulate B cell function and disrupt pathogenic immune responses. This innovative approach could offer improved disease control, reduced adverse events, and new hope for patients facing autoimmune disease.